Based in Maplewood, Minnesota, Solventum Corporation (SOLV) is a healthcare company specializing in the development, manufacturing and commercialization of solutions to meet critical customer and patient needs. It has a market capitalization of $13.2 billion and operates through Medsurg, Dental Solutions, Health Information Systems, and the Cleansing and Filtration segment.
Companies worth more than $10 billion are commonly referred to as “large caps,” and Solventum fits exactly into that category, reflecting its important presence and influence in the healthcare and medical device industries.
Active Investors: Free newsletter behind the hottest stock headlines to uncover new trade ideas
Solv is currently 11.1% below the all-time high of $85.92, which was touched on February 26th. Meanwhile, stocks have skyrocketed 15.6% over the past three months, significantly outpacing the 4.2% profits of Healthcare Select Sector SPDR Fund (XLV) over the same time frame.
www.barchart.com
Solventum has outperformed the healthcare sector in the long term. SOLV has scored 13.4% in the last six months and 10.5% in 52 weeks, with 6.4% in XLV falling over the last six months, surpassing the 2.1% DIP over the past year.
To see the upward trend, SolV has largely surpassed its 50- and 100-day moving averages for most fluctuations since mid-January.
www.barchart.com
Despite offering better than expected finances, Solventum's share price fell 4.4% in the trading session after fourth quarter results were announced on February 27th. Product sales reached $1.6 billion, 2.3% year-on-year. Meanwhile, the company's gross profit fell 3.4% year-on-year to $1.1 billion due to a sharp increase in sales. The company's non-GAAP net profit plummeted to $247 million to 34.1% year-on-year, but the $1.41 EPS surpassed consensus estimates by 7.6%.
However, the company's FY25 guidance missed investors' expectations. Solventum expects organic sales to increase by 2% from a modest 1% to a 2019 rate, with adjusted EPS ranging from $5.45 to $5.65, from $6.70 in 2024. Additionally, the company expects free cash flow to fall from $450 million to $550 million from $855 million in fiscal 2024, shattering investors' trust.
On a positive note, Solv has been Peer Hologic, Inc. over the past six months. (HOLX) 23.8% declined, down 19.4% over the past year.
Nevertheless, analysts are skeptical of the stock outlook. Of the 10 analysts covering SolV Stock, the consensus rating is “pending.” The average price target of $81.14 suggests a modest 6.3% increase from current price levels.
On the date of publication, Aditya Sarawgi had no position (directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, see BarChart's disclosure policy.
The views and opinions expressed herein are the views and opinions of the authors and are not necessarily Nasdaq, Inc. It does not reflect the opinions of
